DaVita's stock surged 25.8% as the company delivered better-than-expected volume growth, raised full-year guidance, and demonstrated early traction from technology investments supporting operational efficiency and clinical outcomes.

• Treatment volume came in slightly ahead of forecast, driven by better-than-expected mortality trends and patient transfers from Fresenius clinic closures.
• Raised full-year volume growth expectations to 25-50 basis points, attributing about half the gain to Fresenius transfers and half to organic improvement.
• Adjusted operating income of $482 million beat internal forecasts by approximately $50 million, with half due to actual performance and half due to timing benefits.
• Adjusted EPS guidance was increased to a $14.10–$15.20 range, reflecting higher volume and lower patient care costs.
• Continued investments in data infrastructure and AI, including deployment of ScheduleHub to optimize scheduling, are positioning the company for operational scale and improved clinical outcomes.